UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience

Journal of allergy and clinical immunology, 2017-05, Vol.139 (5), p.1431-1444

2017

Volltextzugriff (PDF)

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Journal of investigative dermatology, 2020-09, Vol.140 (9), p.1784-1793.e2

2020

Volltextzugriff (PDF)

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.383-389

2010

Volltextzugriff (PDF)

Clinical features of adolescents with chronic idiopathic or spontaneous urticaria

Annals of allergy, asthma, & immunology, 2017-04, Vol.118 (4), p.500-504

2017

Volltextzugriff (PDF)

Long-Term Outcomes from a Pediatric Subgroup of Tenor I: 10 Years Follow up

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB101-AB101

2017

Volltextzugriff (PDF)

Clinical Characteristics of Adolescent Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) in Three Phase III Studies with Omalizumab

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB129-AB129

2015

Volltextzugriff (PDF)

Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the Tenor II Cohort

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB213-AB213

2016

Volltextzugriff (PDF)

Efficacy and Tolerability of Once-Daily Indacaterol 75 μg in COPD Patient Subgroups Defined by Age, Gender, Severity of Airflow Limitation, and Smoking Status

Chest, 2012-10, Vol.142 (4), p.693A-693B

2012

Volltextzugriff (PDF)

Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma

Annals of allergy, asthma, & immunology, 2010-12, Vol.105 (6), p.465-470

2010

Volltextzugriff (PDF)

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Journal of the American Academy of Dermatology, 2017-10, Vol.77 (4), p.667-674

2017

Volltextzugriff (PDF)

Cluster analysis and its application to healthcare claims data: a study of end-stage renal disease patients who initiated hemodialysis

BMC nephrology, 2016-03, Vol.17 (24), p.25-25, Article 25

2016

Volltextzugriff (PDF)

More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II

Journal of allergy and clinical immunology, 2018-05, Vol.141 (5), p.1590-1597.e9

2018

Volltextzugriff (PDF)

The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis

Health and quality of life outcomes, 2006-08, Vol.4 (1), p.50-50, Article 50

2006

Volltextzugriff (PDF)

Clinical Characteristics of Adolescent and Adult Patients with Refractory Chronic Idiopathic Urticaria (ciu) in Three Phase Iii Studies with Omalizumab

Pediatrics (Evanston), 2018-01, Vol.141 (1_MeetingAbstract), p.261-261

2018

Volltextzugriff (PDF)

Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma

Annals of allergy, asthma, & immunology, 2020-02, Vol.124 (2), p.190-196

2020

Volltextzugriff (PDF)

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment

Rheumatology (Oxford, England), 2024-08

2024

Volltextzugriff (PDF)

Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study

Journal of rheumatology, 2022-08, Vol.49 (8), p.894-902

2022

Volltextzugriff (PDF)

A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic Asthma

The Journal of asthma, 2012-03, Vol.49 (2), p.144-152

2012

Volltextzugriff (PDF)

Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort

Annals of allergy, asthma, & immunology, 2021-11, Vol.127 (5), p.593-595

2021

Volltextzugriff (PDF)

15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB38-AB38

2020

Volltextzugriff (PDF)

15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB37-AB37

2020

Volltextzugriff (PDF)

Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials

Annals of allergy, asthma, & immunology, 2017-04, Vol.118 (4), p.500-504

2017

Volltextzugriff (PDF)

Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study

Journal of dermatological science, 2023-01, Vol.109 (1), p.12-21

2023

Volltextzugriff (PDF)

Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-07, Vol.8 (7), p.2243-2253

2020

Volltextzugriff (PDF)

Effect of Omalizumab on Pulmonary Function and Asthma-related Outcome Measures in Patients Allergic to Cat Dander

Clinical immunology (Orlando, Fla.), 2007-01, Vol.123, p.S75-S75

2007

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(39)
Humans
(36)
Female
(25)
Male
(25)
Middle Aged
(22)
Adult
(21)
Treatment Outcome
(20)
Aged
(16)
Adolescent
(15)
Double-Blind Method
(14)
Asthma
(12)
Mathematics
(12)
Allergy
(11)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Allergy And Immunology
(10)
Physical Sciences
(10)
Anti-Asthmatic Agents - Therapeutic Use
(9)
Asthma - Drug Therapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

Clinical features of adolescents with chronic idiopathic or spontaneous urticaria

Long-Term Outcomes from a Pediatric Subgroup of Tenor I: 10 Years Follow up

Clinical Characteristics of Adolescent Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) in Three Phase III Studies with Omalizumab

Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the Tenor II Cohort

Efficacy and Tolerability of Once-Daily Indacaterol 75 μg in COPD Patient Subgroups Defined by Age, Gender, Severity of Airflow Limitation, and Smoking Status

Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Cluster analysis and its application to healthcare claims data: a study of end-stage renal disease patients who initiated hemodialysis

More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II

The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis

Clinical Characteristics of Adolescent and Adult Patients with Refractory Chronic Idiopathic Urticaria (ciu) in Three Phase Iii Studies with Omalizumab

Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment

Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study

A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic Asthma

Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort

15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis

15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis

Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials

Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study

Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II

Effect of Omalizumab on Pulmonary Function and Asthma-related Outcome Measures in Patients Allergic to Cat Dander

Suchergebnisse filtern